Results 141 to 150 of about 36,843 (223)
Impact of ABO-incompatibility on hepatic artery thrombosis in living donor liver transplantation. [PDF]
Kim SH, Park J, Park SJ.
europepmc +1 more source
This study utilized an extensive optimization involving n = 540 design of experiments to produce a superior drainage cannula design. Compared to the clinically used Maquet model, our optimized design demonstrated reduced blood stagnation volumes, increased cannula tip velocities, and higher upper body drainage, potentially minimizing risk of thrombosis
Avishka Wickramarachchi +3 more
wiley +1 more source
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam +4 more
wiley +1 more source
ABSTRACT Background Although portal (venovenous) bypass (pVVB) is uncommon in liver transplantation (LT), it may provide some advantages, particularly for high‐acuity recipients. Methods To examine its use in high‐risk patients, we retrospectively evaluated outcomes of a modified pVVB technique among adult LT recipients at a single center, stratified ...
Michael G. Megaly +10 more
wiley +1 more source
Yuanfei Li,1,* Yong Yang,1,* Yafeng Zheng,2,* Yang Gao,3 Guoliang Shu,4 Wei Gai,2 Yuxin Guo,2 Xianghui Deng1 1Department of Critical Care Medicine, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China ...
Li Y +7 more
doaj
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini +25 more
wiley +1 more source
Overcoming Hepatic Artery Thrombosis After Living Donor Liver Transplantations: An Experience from Asan Medical Center. [PDF]
Park GC +10 more
europepmc +1 more source
ABSTRACT Background & Aim Sustained‐virological‐response (SVR) after direct‐acting‐antiviral (DAA) therapy improves outcomes in patients with HCV‐related compensated‐advanced‐chronic‐liver‐disease (cACLD). However, it remains unclear whether absolute post‐SVR LSM or LSM reduction better predicts prognosis after SVR.
Federica Cerini +6 more
wiley +1 more source

